Table 1 Participant characteristics.

From: The effects of pyrroloquinoline quinone and nicotinamide mononucleotide supplementation on interoception following acute exhaustive exercise: a randomised, double-blind, placebo-controlled study

 

PLC

(n = 15)

PQQ

(n = 15)

NMN

(n = 15)

PN

(n = 15)

Total

(n = 60)

F/χ2

p

Age (year)

19.1 ± 0.9

19.2 ± 0.7

18.9 ± 0.5

19.1 ± 0.8

19.0 ± 0.7

0.58

0.63

Athlete classification, n (%)

     

4.91

0.56

First-class athlete

4 (26.7)

2 (13.3)

1 (6.7)

2 (13.3)

9 (15.0)

  

Second-class athlete

10 (66.7)

10 (66.7)

9 (60.0)

9 (60.0)

38 (63.3)

  

No athletic classification

1 (6.7)

3 (20.0)

5 (33.3)

4 (26.7)

13 (21.7)

  

BMI (kg/m2)

21.7 ± 1.0

21.9 ± 0.8

21.6 ± 0.8

21.8 ± 0.6

21.7 ± 0.6

0.32

0.81

MVPA (min/week)

628.0 ± 415.8

702.7 ± 372.5

670.0 ± 485.3

714.7 ± 426.9

678.8 ± 417.4

0.12

0.95

SB (min/week)

1426.7 ± 504.2

1640.0 ± 640.1

1513.3 ± 459.6

1390.0 ± 609.2

1492.5 ± 552.4

0.59

0.62

RPE

18.9 ± 1.4

18.9 ± 0.7

19.1 ± 1.1

18.4 ± 1.4

18.8 ± 1.2

1.04

0.38

HRmax (bpm)

192.0 ± 8.8

195.3 ± 7.5

195.5 ± 6.3

191.1 ± 7.4

193.5 ± 7.6

1.36

0.27

  1. The values are presented as the number (%) or mean ± SD. BMI Body mass index, MVPA Moderate-to-vigorous physical activity, SB Sedentary behavior, SD Standard deviation.